New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 
• By Sarah Karlin-Smith

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors. 

spotlight focused in center of on an empty stage
Competitor applicants recently have put previously approved drugs back in the advisory committee spotlight. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers